Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma
医学
光动力疗法
尿路上皮癌
癌
肿瘤科
内科学
靶向治疗
癌症研究
癌症
膀胱癌
有机化学
化学
作者
Wesley Yip,Daniel D. Sjoberg,Lucas Nogueira,Andrew Tracey,Ricardo Alvim,Peter A. Reisz,Quinlan Demac,Nicole Benfante,Rand W. Vanden Berg,Kwanghee Kim,Hikmat Al‐Ahmadie,Oscar Lin,Bernard H. Bochner,Guido Dalbagni,S. Machele Donat,Eugene J. Pietzak,A. Ari Hakimi,David B. Solit,Avigdor Scherz,Dean F. Bajorin
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins] 日期:2023-02-01卷期号:209 (5): 863-871被引量:15
Vascular-targeted photodynamic therapy with the intravascular photosensitizing agent padeliporfin (WST-11/TOOKAD-Soluble) has demonstrated therapeutic efficacy as an ablative treatment for localized cancer with potential adaptation for endoscopic management of upper tract urothelial carcinoma. This Phase I trial (NCT03617003) evaluated the safety of vascular-targeted photodynamic therapy with WST-11 in upper tract urothelial carcinoma.